Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model by Roberto Pradas et al.
RESEARCH ARTICLE Open Access
Budget impact analysis of a pneumococcal
vaccination programme in the 65-year-old
Spanish cohort using a dynamic model
Roberto Pradas1*, Angel Gil de Miguel2, Alejandro Álvaro2, Ruth Gil-Prieto2, Reyes Lorente1, Cristina Méndez3,
Pablo Guijarro3 and Fernando Antoñanzas1
Abstract
Background: This study aimed to assess the costs and clinical benefits of the 13-valent pneumococcal conjugate
vaccine (PCV13) administered annually to the 65-year-old cohort in Spain versus the alternative of not vaccinating
patients and treating them only when infected.
Methods: Cases of pneumococcal disease avoided were calculated through a dynamic model based on the work
of Anderson and May (1999). Sixty-six percent of the 65-year-old cohort was assumed to have been vaccinated with
one PCV13 dose (304,492 subjects). Base-case estimated vaccine effectiveness and serotype coverage were 58% and
60%, respectively. Disease-related costs were calculated based on published data.
Results: Over the 5-year period, a total of 125,906 cases of pneumococcal disease would be avoided. Net savings
of €102 million would be obtained. The cost-saving distribution was not homogeneous, starting in the 2nd year
and increasing through the 5th. To demonstrate model robustness, an additional scenario analysis was performed
using extreme values of model parameters (vaccination programme coverage, vaccine effectiveness, discount rate
and disease costs). Under those scenarios, net savings were always achieved.
Conclusions: Based on the assumptions of the model, the 65-year-cohort pneumococcal vaccination campaign
appears to be a cost-saving intervention in the Spanish population under different scenarios.
Background
Streptococcus pneumoniae is a major cause of disease
and death in the adult population [1]. Pneumococcus
accounts for a range of medical conditions including
invasive pneumococcal diseases (IPD) and non-invasive
mucosal infections (non-IPD). The clinical and economic
burden of pneumococcal disease in the adult population
remains high [2,3].
The process of preventing pneumococcal infections with
vaccines has a long history, dating back to the beginning
of 20th century. In Spain, a 23-valent pneumococcal
polysaccharide vaccine (PPV23) is recommended for
adults with certain underlying risk factors as well as all
individuals 65 years of age and older [4,5].
PPV23 has had but limited impact on preventing IPD,
while its effectiveness on mucosal disease (including
community acquired pneumonia - CAP) is at the least
controversial [6].
The routine use of pneumococcal conjugate vaccines,
which induce a T-cell dependent immune response, has
led to a significant reduction in vaccine-preventable
cases of both IPD and non-IPD in young children [7,8].
Conjugate vaccines not only prevent individual cases of
disease directly but also indirectly by reducing disease
transmission. Both effects benefit the health economic
profile of these vaccines.
In 2010, a new 13-valent conjugate vaccine (PCV13) that
widened the spectrum of the former 7-valent conjugate
was licensed to reduce the incidence of pneumococcal
disease in children. An adult indication for the prevention
of pneumococcal disease caused by the serotypes included
in the vaccine has recently been approved.* Correspondence: rpradasvelasco@gmail.com1Universidad de la Rioja, Logroño, La Rioja, Spain
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At present, there is no evidence available regarding the
cost-effectiveness of adult pneumococcal immunization in
the Spanish population. This efficiency, which is illustrated
by the pharmacoeconomic data, is becoming increasingly
important in Public Health decision making.
Several cost-effectiveness studies have recently
been published analysing the economic implications of
implementing an adult pneumococcal immunization
programme with PCV13 [9,10]. Comparisons between
studies are difficult due to differences in methodology
used and assumptions made.
In this context, the work by Rozenbaum et al. [9],
adapted a former model developed by the authors to target
PCV13 use in adults >65 years of age in the Netherlands.
The authors concluded that, with a wide variety of
assumptions, including an effectiveness of 60% against
IPD and non-IPD and compared to a no-vaccination
strategy, there were incremental cost-effectiveness
ratios (ICERs) varying from cost-savings to 50,676€/life
year gained.
Additionally, Smith et al. [10] compared different PCV13
vaccination strategies in the adult population versus no vac-
cination or PPV23. After varying PCV13 effectiveness by
age and patient risk, the authors concluded that, in the
base case scenario (vaccinating at 65 years of age and in
younger high-risk individuals) the cost per quality-
adjusted life year (QALY) was USD 28,900 versus no vac-
cination, and that PCV13 was more efficient than PPV23.
Both publications took into account indirect effects
(herd immunity) using a static approach due to the
Markovian structure of the models used.
The aim of our study was to estimate the cost-
effectiveness of pneumococcal vaccination targeting a
65-year-old cohort versus a no-vaccination strategy
using a transmission-dynamic model. To address this,
we analysed pneumococcal epidemiology in the adult
Spanish population over 50 years of age (15,448,561
inhabitants) [11] and measured the clinical and economic
consequences during the first 5 years.
Methods
Model design
Most of the published pharmacoeconomic models for
infectious diseases use decision trees or Markovian
chains [12]. As mentioned, these type of models assume
a constant force of infection (per-susceptible rate of
infection) during the analysed period and therefore
they do not fully compute the effects of a vaccination
programme [13]. However, the dynamic models used by
epidemiologists [14] capture both direct effects from the
reduction in the number of susceptible individuals and
the indirect effect associated with the reduction of the
number of contacts between susceptible and infected
individuals. The implementation of a pneumococcal
vaccination programme causes both types of effect
because it directly protects vaccinated individuals and, at
the same time, indirectly protects unvaccinated individuals
by limiting the carriage and therefore the transmission of
pneumococcus between individuals [15].
A deterministic Susceptible → Infected → Susceptible
(SIS) model was used, in which individuals who are
susceptible can become infected, after which they return
to the susceptible group once they have recovered. The
SIS model was calibrated to the epidemic behaviour of
the pneumococcal bacterium. If a preventive campaign is
implemented, the susceptible group will be reduced every
year according to the number of individuals effectively
vaccinated (Figure 1); thus, the number of infections
between the susceptible and infected groups is also
reduced.
Differential equation models can be used to model this
epidemic behaviour dynamically [16-18]. Contacts between
infected and susceptible individuals are taken into
account by multiplying their values at each point in time
as [I(t)·S(t)] according to the following non-linear system
of ordinary differential equations:
dS tð Þ
dt
¼ β ⋅ I tð Þ ⋅S tð Þ þ γ ⋅ I tð Þ  V tð Þ
dI tð Þ
dt






where t = time measured in months; I(t) and S(t) = the
number of infected and susceptible individuals, respectively,
at each point in time t; β = the transmission coefficient;
and γ = the coefficient of natural recovery. First order
derivatives with respect to t, dI(t)/dt and dS(t)/dt,
represent the instant rate of variation in time of the
functions associated with the different population classes
Figure 1 Epidemic model.
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(infected and susceptible); V(t), shows the number of
individuals who are vaccinated at each point in time t.
The coefficient of natural recovery (γ) is one indicator of
the rate at which infected individuals again become
susceptible; it depends on how long an individual remains
infected, which is 30 days (τ = 1 month) according to some
authors [19,20]. Our model uses the month as the unit of
time comprising each year; thus γ = 1/τ = 1. By applying a
process of stepwise approximations, we estimated the
transmission coefficient (β=0.000010009257) associated
with the mean annual incidence rate of 563 pneumococcal
infections per 100,000 individuals > 50 years of age
(Table 1).
Adult pneumococcal disease incidence (IPD and non-IPD)
The pneumococcal diseases entered in this model were
primary bacteremia, empyema, meningitis and bacteremic
pneumonia (IPD), and hospitalized and out-patient
pneumococcal pneumonia (non-IPD).
The pneumococcal disease incidence rate was calculated
using the published number of hospitalized CAP cases in
the Spanish population >50 years of age over a 5-year
period (447,670 CAP discharges from 2003 to 2007) [21].
For this model, it was estimated that 50% of CAP cases
were caused by Streptococcus pneumoniae [22].
In addition, according to several authors, 40% of CAP
cases in adults do not require hospitalization, and those
were considered out-patient pneumococcal pneumonia
[23]. Finally, based on published data, an incidence rate
of 30 IPD cases per 100,000 individuals was used [24].
Pneumococcal force of infection
The model associated the force of infection with the
number of individuals infected at each point in time
λ(t)= β·I(t). The transmission coefficient (β) represents
the probability of a contact between a susceptible and
an infected individual leading to transmission of the
infection. Due to its high precision, a 4th order
Runge–Kutta method was used to solve the differential
equation system [25,26]. Figure 2 shows the proper
adjustment between the historical series of infections and
the series of values generated by the model.
The system deals with vaccination progressively
according to the following functions:
V tð Þ ¼
0 if 1≤ t ≤ 2
V
2
if 2< t ≤ 4




where V is the hypothetical number of individuals actually
vaccinated in each annual campaign. The pneumococcal
vaccine is co-administered together with the influenza
vaccine, as recommended, for specific groups [27].
The time is measured in months, one year being the
epidemiologic period to run the model.
According to the recommendations of the Spanish
National Centre for Epidemiology, the epidemiologic year
for influenza starts in August (month 1) and it concludes
in August of the following year. The interval in which V(t)
is not zero is the same as the interval associated with the
vaccination campaign (October and November).
Population, vaccine effectiveness, serotype and vaccine
coverage
The target population for the vaccination programme is
the 65-year-old cohort, but consequences were measured
in the population >50 years of age. Although people enter
the population >50 years of age through aging or migration
Figure 2 Annual rate of pneumococcal infections [21-26].








Prevenar 13W exfactory price/dose 49,91
Table 1 Mean annual incidence (cases per 100,000)
[21-24]
Pneumococcal disease Cases
NON-IPD Hospitalized pneumonia 318.75
Out-patient pneumonia 214.27
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and people leave it because of death or migration, we
assumed that the population >50 years of age would
not significantly change during the study period.
Therefore the composition of the population >50 years
of age was not changed in the model. In the base case
scenario, as in previous published studies [9], a weighted
mean vaccine effectiveness of 58% for both IPD and
non-IPD (mainly non-bacteremic pneumococcal pneu-
monia) was assumed. It was assumed that the vaccination
programme would reach an annual coverage of 66%,
which is similar to the 2009–10 influenza programme
[28]. The proportion of IPD and non-IPD cases covered
by the serotypes included in the PCV13 vaccine was
assumed to be 60%, which is a little lower than the 66%
serotype coverage rate reported for 2009 in the Madrid
region for persons over 59 years of age [29].
Costs
The costs associated with pneumococcal disease, in
euros for the year 2010, were determined according to
published data in the Spanish population [23,24]. The
cost of the vaccination programme was calculated using
the official price of PCV13 [30] (Table 2).
Sensitivity analysis
In order to minimize model uncertainty, a sensitivity
analysis was performed with two alternative scenarios.
In those scenarios, vaccination coverage and vaccine
effectiveness varied from 60% to 80% and from 40%
to 75%, respectively, but serotype coverage remained
unchanged.
Additionally, pneumococcal disease-related costs and
discounts rates were also modified to broaden the sensitivity
analysis spectrum, and those are described in Table 3.
Programme effectiveness
All patients would receive a single dose of PCV13. The
annual number of effectively vaccinated individuals was
calculated based on vaccine effectiveness and serotype and
vaccination coverage. So it varies within model scenarios
as depicted in Table 4 [11]. PCV13 is considered safe
and rarely causes any severe adverse event. Neither
adverse events nor their related costs were considered in
this model.
Time horizon, perspective and estimated benefits
Analyses were undertaken from the Spanish Public
Healthcare System perspective. Only direct costs were
estimated, and results were expressed as the number of
pneumococcal infections avoided, as this is the primary
outcome generated by the differential equation system of
the epidemiological dynamic model. Both clinical and
economic consequences were measured during the
first 5 years. According to the published Spanish
recommendations [31], the discount rate applied for
costs was 3%.
Results
Number of avoided infections
Implementation of a pneumococcal vaccination programme
with PCV13 in a 65-year-old cohort would help to
significantly reduce both the clinical and the economic
burden caused by Streptococcus pneumoniae.
In the base case analysis, there would be a reduction
of more than 125,000 pneumococcal cases compared to
no vaccination (Table 5).
The number of cases averted grows over time due to
the progressive accumulation of vaccinated individuals.
As the number of vaccinated individuals increases, the
number of susceptible individuals decreases, and therefore
there is a reduction in contacts between infected and
susceptible individuals. Averted cases of pneumococcal
disease were mainly cases of hospitalized pneumococcal
pneumonia, followed by out-patient pneumococcal
pneumonia (Table 6).
Introduction of a pneumococcal vaccination programme
with PCV13 in a 65-year-old cohort would be a
cost-saving measure. Vaccination costs would be offset
Table 4 Coverage of the pneumococcal vaccination programme [11]
Scenario Vaccinated annually Effectively vaccinated annually Effectively vaccinated five-yearly
Unfavorable 278,074 66,738 333,689
Base 304,492 105,963 529,815
Favorable 370,766 166,845 834,223




Vaccination coverage 66% 60% 80%
PCV13 Effectiveness 58% 40% 75%
Serotype Coverage 60% 60% 60%
Hospitalized pneumonia cost 1,983 1,785 2,181
Out-patient pneumonia cost 250 225 275
Primary bacteremia cost 4,093 3,684 4,502
Empyema cost 5,954 5,359 6,549
Meningitis cost 11,202 10,082 12,322
Bacteremic pneumonia cost 5,420 4,878 5,962
Discount rate (costs) 3% 5% 0%
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by cost saving for avoided cases of pneumococcal disease.
Programme savings would be mainly generated by averted
cases of hospitalized pneumonia followed by averted cases
of bacteremic pneumonia (Table 6).
Sensitivity analysis
In the sensitivity analysis, although many parameters were
modified in favourable and unfavourable ways, results
were minimally affected. Even in the worst case scenario,
we found that globally 88,366 pneumococcal cases would
be averted (divided into 83,848 non-IPD and 4,518 IPD
cases). In this conservative scenario, PCV13 resulted in
cost savings as of the third year after the start of the
programme and continues going forward (Table 7).
Discussion
The three scenarios analyzed in our dynamic model
suggest that, after three years, the 65-year-old cohort
pneumococcal vaccination campaign appears to be a
cost-saving measure in Spain. The avoided cases of
hospitalized pneumococcal pneumonia (bacteremic and
non-bacteremic) are responsible for the majority of the
cost savings.
Since the vaccination programme generates savings
under all 3 scenarios studied and prevents cases of
pneumococcal disease, calculating the cost-effectiveness
and cost-utility ratio in terms of life years gained would
have not provided additional information. Therefore
estimation efforts concerning number of deaths prevented
and impact on population quality of life, although
interesting from a public health point of view, would have
unnecessarily complicated the modelling without adding
information to assist decision makers.
Strengths and weaknesses
This is the first evaluation of a national adult pneumococcal
immunization programme with PCV13 using a dynamic
model. Compared to other techniques, the use of differen-
tial equations captures the indirect effect of the
vaccination programme for estimating health outcomes.
This model adjusts fairly well to the pattern of the infect-
ive agent in the study population. The sensitivity analysis
also showed that the model results were robust to
changes in the parameters analyzed. The model
Table 6 Clinical and economic effects of the vaccination programme
Results Year Five-year results
1 2 3 4 5
Base scenario
Avoided hospitalized pneumonias 1,134 5,755 13,078 21,471 29,998 71,436
Avoided outpatient pneumonias 762 3,869 8,792 14,434 20,166 48,022
Avoided primary bacteremias 31 156 313 572 686 1,758
Avoided empyemas 0 2 4 8 9 24
Avoided meningitis 10 51 103 189 226 579
Avoided bacteremic pneumonias 71 363 728 1,330 1,594 4,087
Avoided contagions 2,008 10,196 23,018 38,004 52,680 125,906
Hospitalized pneumonia cost savings 2,247,819 11,411,544 25,933,983 42,577,699 59,486,125 141,657,169
Outpatient pneumonia cost savings 190,504 967,134 2,197,917 3,608,480 5,041,478 12,005,513
Primary bacteremias cost savings 125,824 639,232 1,281,675 2,341,411 2,807,267 7,195,409
Empyemas cost savings 2,486 12,628 25,319 46,254 55,457 142,145
Meningitis cost savings 113,513 576,685 1,156,266 2,112,310 2,532,584 6,491,358
Bacteremic pneumonias cost savings 387,336 1,967,803 3,945,487 7,207,762 8,641,848 22,150,236
Savings by all cases averted 3,067,481 15,575,025 34,540,648 57,893,917 78,564,759 189,641,830
Cost of vaccinations 15,197,172 15,197,172 15,197,172 15,197,172 15,197,172 75,985,862
Net healthcare cost 12,129,691 −377,853 −19,343,475 −42,696,744 −63,367,587 −113,655,968
Discounted net healthcare cost 12,129,691 −366,848 −18,233,081 −39,073,569 −56,301,280 −101,845,087








1 86,049 84,040 2,008
2 86,512 76,316 10,196
3 86,976 63,957 23,018
4 87,439 49,435 38,004
5 87,902 35,223 52,680
Total 5 years 434,878 308,972 125,906
Estimated cases of pneumococcal disease avoided include IPD and non-IPD
(out-patient pneumococcal pneumonia and hospitalized pneumococcal
pneumonia).
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economic outcomes were minimally sensitive to
changes in vaccination coverage and PCV13 effectiveness.
Modelling the epidemiological impact of pneumococcal
vaccination in adults is challenging due to several
elements that have an impact on intervention outcomes
and required some assumptions. Cohort and population
models highlight different aspects of the infectious disease
process and, therefore, we have only answered part of
the questions raised about pneumococcal vaccination
implementation [32]. We estimated the unknown
effectiveness of PCV13 in adults and tried to minimize
its uncertainty by using a sensitivity analysis. Additionally,
pneumococcal nasopharyngeal carriage and adult-to-adult
transmission patterns are not yet well understood.
In Spain, PCV13 is only included in the National
Immunization Programmes for infants in Madrid [33]
Table 7 Sensitivity analysis results
Results Year Five-year results
1 2 3 4 5
Unfavourable scenario
Avoided hospitalized pneumonias 785 3,749 8,690 14,925 21,993 50,141
Avoided outpatient pneumonias 528 2,520 5,841 10,033 14,784 33,707
Avoided primary bacteremias 21 102 208 398 503 1,232
Avoided empyemas 0 1 3 5 7 17
Avoided meningitis 7 34 69 131 166 406
Avoided bacteremic pneumonias 49 237 484 924 1,169 2,863
Avoided contagions 1,390 6,643 15,294 26,417 38,621 88,366
Hospitalized pneumonia cost savings 1,400,564 6,691,314 15,508,174 26,637,024 39,250,376 89,487,451
Outpatient pneumonia cost savings 118,698 567,092 1,314,325 2,257,501 3,326,488 7,584,104
Primary bacteremias cost savings 78,398 374,823 766,424 1,464,809 1,852,303 4,536,757
Empyemas cost savings 1,549 7,405 15,141 28,937 36,592 89,623
Meningitis cost savings 70,727 338,147 691,432 1,321,482 1,671,060 4,092,848
Bacteremic pneumonias cost savings 241,340 1,153,848 2,359,348 4,509,247 5,702,099 13,965,882
Savings by all cases averted 1,911,277 9,132,628 20,654,844 36,218,999 51,838,917 119,756,665
Cost of vaccinations 13,878,696 13,878,696 13,878,696 13,878,696 13,878,696 69,393,481
Net healthcare cost 11,967,420 4,746,068 −6,776,147 −22,340,303 −37,960,221 −50,363,184
Discounted net healthcare cost 11,967,420 4,520,065 −6,146,165 −19,298,394 −31,229,968 −40,187,043
Favourable scenario
Avoided hospitalized pneumonias 1,744 8,632 18,959 29,239 38,179 96,754
Avoided outpatient pneumonias 1,172 5,803 12,745 19,656 25,666 65,042
Avoided primary bacteremias 47 234 454 779 873 2,387
Avoided empyemas 1 3 6 11 12 32
Avoided meningitis 16 77 150 257 288 787
Avoided bacteremic pneumonias 110 545 1,055 1,811 2,029 5,550
Avoided contagions 3,090 15,294 33,369 51,753 67,047 170,552
Hospitalized pneumonia cost savings 3,804,001 18,829,047 41,355,130 63,780,008 83,280,575 211,048,761
Outpatient pneumonia cost savings 322,391 1,595,771 3,504,867 5,405,386 7,058,069 17,886,484
Primary bacteremias cost savings 212,934 1,054,733 2,043,798 3,507,357 3,930,174 10,748,996
Empyemas cost savings 4,206 20,836 40,375 69,287 77,640 212,345
Meningitis cost savings 192,099 951,530 1,843,818 3,164,172 3,545,617 9,697,236
Bacteremic pneumonias cost savings 655,491 3,246,874 6,291,595 10,769,994 12,098,587 33,089,542
Savings by all cases averted 5,191,122 25,698,792 55,079,583 86,723,204 109,990,663 282,683,364
Cost of vaccinations 18,504,928 18,504,928 18,504,928 18,504,928 18,504,928 92,524,641
Net healthcare cost 13,313,807 −7,193,863 −36,574,655 −68,218,276 −91,485,735 −190,158,723
Discounted net healthcare cost 13,313,807 −7,193,863 −36,574,655 −68,218,276 −91,485,735 −190,158,723
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(2+1, since June 2010 with 96.3% uptake) and Galicia
(2+1, since January 2012); these regions account for 19%
of the Spanish population of all ages. So the childhood
vaccination coverage within the country is uneven. For
this reason, the potential herd effect from vaccinating the
paediatric population has not been taken into account in
the present model.
On the other hand, a potential additional effect of
PPV23 on IPD cases in adults older than 65 years of age
was not taken into account because we introduce the
remaining burden of disease into the model after its
long-term use.
Another limitation is that we did not take into
account the potential increase in pneumococcal disease
caused by serotypes not included in the PCV13. As there
is currently no data available on the emergence of
non-PCV13 serotypes, such a scenario was impossible
to model.
This analysis did not include mortality rates and disease
sequelae from pneumococcal disease. Having not
incorporated mortality in our study should be considered
as a model limitation. On the other hand, the implementa-
tion of an immunization programme in adults would
increase population life expectancy and patient quality of
life, which would further increase the benefit associated
with this intervention. Additionally, we did not include
indirect costs as this study has adopted a healthcare
system perspective, so the vaccine value could have been
underestimated. Although our model did not take into
account the impact of the vaccine on patient quality of
life, it would be interesting to measure how invasive and
non-invasive pneumococcal disease influences quality of
life. An appropriate instrument would be the EQ-5D,
already used for other diseases such as the influenza, in
the Spanish context [34].
Conclusions
In conclusion, despite the inherent limitations of this
model, the analysis suggests that a 65-year-old cohort
vaccination programme with PCV13 in Spain would
avoid a large number of cases of pneumococcal disease
over a 5-year period and would be a cost-saving measure
from a healthcare system perspective.
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